Improved overall survival in melanoma with combined dabrafenib and trametinib.

  title={Improved overall survival in melanoma with combined dabrafenib and trametinib.},
  author={Caroline Robert and Boguslawa Karaszewska and Jacob M Schachter and Piotr Z. Rutkowski and Andrzej Mackiewicz and Daniil Stroiakovski and Michael R Lichinitser and Reinhard Dummer and F Grange and Laurent Mortier and Vanna Chiarion-Sileni and Kamil Drucis and Ivana Krajsov{\'a} and A. H. W. Hauschild and Paul C. Lorigan and Pascal Wolter and Georgina V Long and Keith T. Flaherty and Paul N Nathan and Antoni Ribas and A M Martin and Peng Sun and Wendy Cunningham Monica Yant Amy Eckert Kristin Costello Crist and Jeff Legos and Stephen D. Rubin and Shonda M Little and Dirk Schadendorf},
  journal={The New England journal of medicine},
  volume={372 1},
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients. METHODS In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a… CONTINUE READING
Highly Influential
This paper has highly influenced 27 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 105 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 519 extracted citations


Publications referenced by this paper.
Showing 1-10 of 27 references

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72

  • CM Johannessen, JS Boehm, SY Kim
  • Copyright © 2014 Massachusetts Medical Society…
  • 2014

Similar Papers

Loading similar papers…